PEDIATRICS Vol. 90 No. 5 November 1992, pp. 781
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by JONES, R. A.K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JONES, R. A.K.

The "Dose" Question

R. A.K. JONES 1, A. M. GRANT 1, and the Collaborative Dexamethasone Trial Group1

1 Perinatal Trials Service, NPEU, Radcliffe Infirmary, Oxford, OX2 6HE England

To the Editor.—

In our recent report of the collaborative trial of dexamethasone therapy for chronic neonatal lung disease1 we quoted a dosage schedule for dexamethasone of 0.6 mg/kg/d and omitted stating that the product used (Decadron, Merck, Sharp & Dohme) is supplied as dexamethasone sodium phosphate. After allowing for the sodium and phosphate, this is equivalent to a dose of 0.5 mg/Kg/d dexamethasone base.

Mammel and colleagues2 in the first published report of a controlled trial of dexamethasone for chronic neonatal lung disease, stated that they gave dexamethasone in a dose of 0.5 mg/kg/d.